Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2019-03-27 Earnings Release
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
IL CONSIGLIO DI AMMINISTRAZIONE DI KOLINPHARMA SPA APPROVA IL PROGETTO DI BILANCIO AL 31 DICEMBRE2018
Earnings Release Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from KOLINPHARMA S.p.A. dated March 27, 2019. The subject line explicitly states: 'KOLINPHARMA SPA APPROVA IL PROGETTO DI BILANCIO AL 31 DICEMBRE 2018' (KOLINPHARMA SPA APPROVES THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018). The text provides key financial highlights (Revenues, EBITDA, Net Result) for the year ended December 31, 2018, and mentions the approval of the draft financial statements by the Board of Directors. It also announces the date for the Shareholders' Meeting to approve the final statements. This content strongly aligns with an Earnings Release (ER) which announces periodical financial results, even though it contains more detail than a typical press release, it is the initial announcement of the annual results. It is not the full 10-K, nor is it a comprehensive Interim Report (IR) since it covers the full year. The presence of key financial figures and management commentary on the annual performance points to an Earnings Release (ER). The document also explicitly lists the attached financial statements (Stato patrimoniale, Conto economico, Rendiconto finanziario), confirming its nature as a results announcement. FY 2018
2019-03-27 Italian
dimissioni amministratore delegato-deleghe attribuite al presidente Rita Paola Petrelli
Board/Management Information Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from KOLINPHARMA S.p.A. dated January 30, 2019. The subject ('Oggetto') explicitly states 'dimissioni amministratore delegato-deleghe attribuite al presidente Rita Paola Petrelli' (resignation of the CEO - powers attributed to the president). The body confirms the resignation of the CEO and the reallocation of his duties to the President. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in senior management.
2019-01-30 Italian
KOLINPHARMA-CALENDARIO EVENTI SOCIETARI 2019
Report Publication Announcement Classification · 1% confidence The document is a formal announcement from KOLINPHARMA S.p.A. dated January 28, 2019, titled 'KOLINPHARMA-CALENDARIO EVENTI' (KOLINPHARMA-EVENTS CALENDAR). It explicitly lists the schedule for key corporate events throughout 2019, including the Board Meeting for the 2018 financial statements approval, the Shareholders' Meeting (Assemblea degli Azionisti) for the same approval, and the subsequent Board Meeting for the half-year report approval. This document is not the actual financial report (like 10-K or IR), nor is it a transcript or a general press release. It is an announcement detailing the timing of future corporate reporting events. This fits the definition of a Report Publication Announcement (RPA), which signals when reports will be released, or potentially a Regulatory Filing (RNS) if RPA is too specific. Given the content is strictly a schedule of future report releases (financial statements, half-year report), RPA is the most precise fit, as it announces the publication schedule.
2019-01-28 Italian
Price sensitive Comunicato Stampa Lancio Nuovo Prodotto: MILEDIX
Regulatory Filings Classification · 1% confidence The document is an official regulatory filing ('Informazione Regolamentata') from KOLINPHARMA S.p.A., dated January 8, 2019. The subject ('Oggetto') is 'Nuovo Prodotto: MILEDIX' and it is explicitly labeled as a 'Price sensitive Comunicato Stampa Lancio' (Price sensitive Press Release Launch). It announces the launch of a new product (MILEDIX) during the company's annual convention. Since this is a price-sensitive announcement regarding a new product launch, it fits the description of an Earnings Release (ER) if it were financial results, but since it is a product launch announcement, it is most closely related to a general regulatory announcement or a specific type of press release. Given the options, this is a significant, price-sensitive announcement that doesn't fit the specific financial report types (10-K, IR, ER). It is a general regulatory announcement that is price-sensitive. The closest fit among the provided codes for a significant, non-financial-result, price-sensitive announcement that is not a management change or capital event is RNS (Regulatory Filings), which serves as a general regulatory announcement fallback. However, the content is a press release announcing a new product, which is often categorized separately. Since there is no specific 'Product Launch Announcement' code, and it is a formal regulatory disclosure ('Informazione Regolamentata'), RNS is the most appropriate fallback. If we consider the content as a major business update that impacts valuation, it is a regulatory filing.
2019-01-08 Italian
comunicato proce sensitive- rinnovo approvazione Modello L.231
Governance Information Classification · 1% confidence The document is an Italian 'Informazione Regolamentata' (Regulated Information) from KOLINPHARMA S.p.A., dated December 13, 2018. The subject ('Oggetto') is 'comunicato proce sensitive- rinnovo approvazione Modello L.231' (sensitive procedure communication - renewal of approval of Model L.231). The text explicitly discusses the renewal of the adoption of the 'Modello di Organizzazione, Gestione e Controllo' pursuant to Legislative Decree 231/2001 and the Code of Ethics, and the confirmation of the Supervisory Body (OdV). This relates directly to the company's internal rules, board structure, and governance practices. This content aligns perfectly with the definition of Governance Information (Code: CGR), which covers internal rules and board structure. It is not an Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR). Since it is a formal announcement detailing governance structure updates, CGR is the most specific fit, rather than the general Regulatory Filings (RNS). The document length is short (under 5,000 characters) and it directs readers to the website for the full documents, but the core content is the governance update itself, making CGR more appropriate than RPA.
2018-12-13 Italian
Pubblicato nuovo sito in 5 lingue e nuova sezione "brevetti"
Regulatory Filings Classification · 1% confidence The document is a formal announcement from KOLINPHARMA S.p.A. dated November 6, 2018, identified as 'Informazione Regolamentata' (Regulated Information) under AIM-Italia. The subject ('Oggetto') is 'sezione "brevetti"' (patents section), and the text announces the launch of a new, multilingual corporate website, including a new section dedicated to patents. This type of communication, which announces a corporate development (website launch) via a regulated channel, fits best as a general regulatory announcement or a specific corporate update that isn't strictly financial results (ER/IR), management change (MANG), or dividend (DIV). Since it is a formal, regulated disclosure that doesn't fit the highly specific categories like 10-K, ER, or DIRS, the most appropriate general category is Regulatory Filings (RNS). Although it announces a corporate update, RNS serves as the best fit for miscellaneous regulatory disclosures not covered elsewhere, especially given the structure of the filing metadata (Informazione Regolamentata). The document length is relatively short (4916 chars) and it is an announcement, not the full report itself.
2018-11-06 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.